Glutamine-donor peptides

Z-Gln-Gly-CAD-TAMRA



Order
Quantity
Price
Status
25 mg 500 € available


Documents
Art. No. C090
Molecular Formula C45H51N7O9
Molecular Weight 833.93
Purity by HPLC >95 % (HPLC)
Appearance Deep red solid
Solubility Dissolve e.g. the complete 25 mg (adjust to the weight given on the vial) in 299.8 μL DMSO to obtain a 100 mM stock solution. Dilution of 1:1000 in your final assay would result in 100 μM with an acceptable DMSO concentration of 0.1%.
DMSO stock solutions are sterile and can be stored at -20°C for at least 6 months. To avoid too many freeze-thaw cycles, we strongly recommend storage of aliquots.
Application Glutamine donor substrate for transglutaminases
λex = 547 nm; λem = 573 nm[1]
[1] Aneja A. et al. J. Biol. Phys. 2008, 34, 487.
Storage Store at -20°C, desiccate
Reference(s) Spycher, P.R. et al. ChemBioChem 2017, 18, 1923-7.
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy